Activity of Selected Group of Monoterpenes in Alzheimer's Disease Symptoms in Experimental Model Studies-A Non-Systematic Review
Alzheimer's disease (AD) is the leading cause of dementia and cognitive function impairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation substances are most desirable because they improve cognition with minimal side effects. Plant secondary metabolites, used in traditional medicine and pharmacy, are promising. Among these are the monoterpenes-low-molecular compounds with anti-inflammatory, antioxidant, enzyme inhibitory, analgesic, sedative, as well as other biological properties. The presented review focuses on the pathophysiology of AD and a selected group of anti-neurodegenerative monoterpenes and monoterpenoids for which possible mechanisms of action have been explained. The main body of the article focuses on monoterpenes that have shown improved memory and learning, anxiolytic and sleep-regulating effects as determined by in vitro and in silico tests-followed by validation in in vivo models.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
---|---|
Enthalten in: |
International journal of molecular sciences - 22(2021), 14 vom: 08. Juli |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wojtunik-Kulesza, Karolina [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 17.08.2021 Date Revised 17.08.2021 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/ijms22147366 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM328438561 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM328438561 | ||
003 | DE-627 | ||
005 | 20231225202931.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/ijms22147366 |2 doi | |
028 | 5 | 2 | |a pubmed24n1094.xml |
035 | |a (DE-627)NLM328438561 | ||
035 | |a (NLM)34298986 | ||
035 | |a (PII)7366 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wojtunik-Kulesza, Karolina |e verfasserin |4 aut | |
245 | 1 | 0 | |a Activity of Selected Group of Monoterpenes in Alzheimer's Disease Symptoms in Experimental Model Studies-A Non-Systematic Review |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 17.08.2021 | ||
500 | |a Date Revised 17.08.2021 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Alzheimer's disease (AD) is the leading cause of dementia and cognitive function impairment. The multi-faced character of AD requires new drug solutions based on substances that incorporate a wide range of activities. Antioxidants, AChE/BChE inhibitors, BACE1, or anti-amyloid platelet aggregation substances are most desirable because they improve cognition with minimal side effects. Plant secondary metabolites, used in traditional medicine and pharmacy, are promising. Among these are the monoterpenes-low-molecular compounds with anti-inflammatory, antioxidant, enzyme inhibitory, analgesic, sedative, as well as other biological properties. The presented review focuses on the pathophysiology of AD and a selected group of anti-neurodegenerative monoterpenes and monoterpenoids for which possible mechanisms of action have been explained. The main body of the article focuses on monoterpenes that have shown improved memory and learning, anxiolytic and sleep-regulating effects as determined by in vitro and in silico tests-followed by validation in in vivo models | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Alzheimer’s disease | |
650 | 4 | |a anxiolytic activity | |
650 | 4 | |a insomnia | |
650 | 4 | |a memory | |
650 | 4 | |a monoterpenes | |
650 | 4 | |a sleep regulatory | |
650 | 7 | |a Anti-Anxiety Agents |2 NLM | |
650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
650 | 7 | |a Antioxidants |2 NLM | |
650 | 7 | |a Apolipoproteins E |2 NLM | |
650 | 7 | |a Cholinesterase Inhibitors |2 NLM | |
650 | 7 | |a Iridoids |2 NLM | |
650 | 7 | |a Monoterpenes |2 NLM | |
650 | 7 | |a Nerve Tissue Proteins |2 NLM | |
650 | 7 | |a Neuroprotective Agents |2 NLM | |
650 | 7 | |a Nootropic Agents |2 NLM | |
650 | 7 | |a Polyphenols |2 NLM | |
650 | 7 | |a Acetylcholinesterase |2 NLM | |
650 | 7 | |a EC 3.1.1.7 |2 NLM | |
650 | 7 | |a Acetylcholine |2 NLM | |
650 | 7 | |a N9YNS0M02X |2 NLM | |
700 | 1 | |a Rudkowska, Monika |e verfasserin |4 aut | |
700 | 1 | |a Kasprzak-Drozd, Kamila |e verfasserin |4 aut | |
700 | 1 | |a Oniszczuk, Anna |e verfasserin |4 aut | |
700 | 1 | |a Borowicz-Reutt, Kinga |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 22(2021), 14 vom: 08. Juli |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
773 | 1 | 8 | |g volume:22 |g year:2021 |g number:14 |g day:08 |g month:07 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms22147366 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 22 |j 2021 |e 14 |b 08 |c 07 |